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Background
Over 90% of allergic rhinitis (AR) patients have ocular
symptoms during the pollen season, but these are routi-
nely neglected and under-treated. New treatment
options should provide relief not only from all nasal
symptoms, but all ocular symptoms too, since patients
frequently present with symptoms from both nasal and
ocular origin. The reflective total of 7 symptom scores
(rT7SS) is an endpoint measuring the entire AR symp-
tom complex. It comprises both the reflective total nasal
symptom score (rTNSS) and the reflective total ocular
symptom score in one global score (max score=42).
Objective
To assess the efficacy of MP29-02* (a novel intranasal
formulation of azelastine hydrochloride [AZE] and fluti-
casone propionate [FP]) in providing relief from the
entire AR symptom complex compared to commercially
available intranasal AZE or FP nasal sprays and placebo,
in patients with seasonal AR (SAR).
Methods
610 patients (>=12 years old) with moderate-to-severe
SAR were randomized into this double-blind, placebo-
controlled, 14-day, parallel-group trial to MP29-02*,
commercially-available AZE or FP nasal sprays, and pla-
cebo (all given as 1 spray/nostril bid [total daily doses:
AZE = 548 µg; FP=200 µg]. The primary efficacy vari-
able was change from baseline in rTNSS (AM +PM),
over 14-days. Change from baseline in rT7SS was
assessed post-hoc via an analysis of covariance.
Results
MP29-02* most effectively treated the entire rhinitis
symptom complex, reducing the rT7SS from baseline by
-8.74 compared to -6.05 for FP (Diff: -2.69; 95% CI:
-4.33, -1.06; p=0.0013), -5.83 for AZE (Diff -2.91; 95%
CI: -4.52, -1.31; p=0.0004) and -3.55 for placebo (Diff
-5.19; 95% CI: -6.71, -3.68; p<0.0001). The relative dif-
ference was 52% to FP and 56% to AZE, making MP29-
02* twice as effective as either firstline therapy. This
benefit was observed during the first day of treatment
and was sustained over the entire course of treatment.
Conclusion
Compared to currently available first-line therapy for AR,
MP29-02* most effectively treats the entire rhinitis symp-
tom complex, comprising the most commonly reported
nasal and ocular symptoms. Such a universal treatment
option should preclude the need for concomitant eye
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